Recently Signed Customer Scales Kneat’s platform to Second Site
HALIFAX, February 14, 2019/CNW/ – kneat.com, inc. (TSX-V: KSI) (“Kneat”) is pleased to announce that a top tier global healthcare customer is expanding their use of the Kneat platform to a new manufacturing site. This customer was signed in July 2018, went live at their primary European site in December 2018 and is now expanding to a second site located in the United States.
This customer’s initial deployment was for commissioning and qualification (‘C&Q’). The new site will utilize the Kneat platform to leverage their C&Q framework that was centrally configured at the European site. The plan is to go-live at the second site within six to eight weeks. Kneat’s innovative design enables any global site to centrally manage their processes in a controlled and compliant manner while facilitating a transition to fully paperless and standardized validation processes.
“In 2018 we signed seven multinational customers in the life sciences industry and three went live in the second half of 2018 with initial deployments. All three are now expanding their use of the platform. The other four customers are now in the process of their initial deployment and we look forward to working with them as they go-live,” said Eddie Ryan, Chief Executive Officer of Kneat.
Kneat continues to expand its customer pipeline and will report on further developments as they occur.
About Kneat
Kneat, develops and markets the next generation Kneat Gx software platform. Multiple business processes can be configured on the platform from equipment to computer system validation, through to production record execution and quality document management. Kneat Gx allows users to author, review, approve, execute testing online, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11/ Eudralex Annex 11 compliant platform. Macro and micro report dashboards enable powerful oversight into all systems, projects and processes world wide. Customer case studies are reporting productivity improvements in excess of 100% and a higher compliance standard. For more information visit www.kneat.com.
Cautionary and Forward-Looking Statements
Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the relationship between Kneat and the customer, the Company’s business development activities, the use of Kneat within the customer’s manufacturing process, the ability to scale the use of Kneat within the customer and the compliance of the Kneat Gx platform under regulatory audit and inspection. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investors’ own risk.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information: Sarah Oliver, CFO, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: inquiry@kneat.com